2026-04-17T13:55:19Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4629482024-11-04T04:14:40Zcom_2072_98col_2072_378192

Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers : A case series of 20 patients Alijotas-Reig, Jaume García-Gimenez, Victor Velthuis, Peter J. Niessen, Frank B. Decates, Tom S. Adverse reactions COVID-19 Inflammation SARS-CoV-2 Soft tissue fillers Altres ajuts: acords transformatius de la UAB Background: Adverse events (AE) after COVID-19 vaccines, particularly, but not solely, with those messenger RNA (mRNA)-based vaccines, have rarely been reported in patients previously treated with dermal fillers (DF). Objective: To evaluate the morphology, clinical characteristics, the timing of presentation, and outcomes of inflammatory AE appeared in patients injected with DF, after anti-COVID-19 vaccination. Methods: Descriptive study of a case series of 20 consecutive patients collected after the occurrence of AE in previously filled areas post COVID-19 vaccination. Results: From January 2021 to July 2021, we analyzed 20 AE reactions triggered by COVID-19 vaccines in the previously mentioned cohort. They were vaccinated with Pfizer/Biontech (11; 55%), Moderna (5; 25%), Astra-Zeneca (3; 15%), and Sputnik (1; 5%). The most common manifestations were oedema/swelling, angioedema, erythema, skin induration, and granuloma. Less common reactions included myalgia and lymphadenopathy. In 13/20 (65%) cases, the AE appeared after the first dose of vaccine. These inflammatory AE appeared more rapidly after the second dose than after the first one. In 13/20 (65%) cases, the symptomatology subsided with anti-inflammatory/antihistaminic drugs, while spontaneously in 3/20 (15%). The manifestations are ongoing.in the remaining four cases (20%). Conclusion: Although probably rare, both RNA-based and adenovirus-based anti-COVID-19 vaccines can cause inflammatory bouts in patients previously treated with DF. In these cases, caution should be paid on subsequent vaccine doses, considering a tailored risk/benefit for any case before next vaccination. 2022 Article https://ddd.uab.cat/record/264406 urn:10.1111/jocd.15117 urn:oai:ddd.uab.cat:264406 urn:scopus_id:85131553756 urn:pmid:35621234 urn:pmc-uid:9347616 urn:pmcid:PMC9347616 urn:oai:pubmedcentral.nih.gov:9347616 urn:oai:egreta.uab.cat:publications/0032c0d8-f190-4913-81fb-e4364e57e2da http://hdl.handle.net/2072/462948 eng Journal of Cosmetic Dermatology ; 2022 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. https://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf